Search
Benserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalIn particular, although the specific levodopa/benserazide combination is formally approved for use in Canada and much of Europe, the FDA has approved another similar levodopa/dopa decarboxylase inhibitor … Moreover, the European Medcines Agency has conferred an orphan designation upon benseraside since 2015 for its potential to be used as a therapy for beta thalassaemia as well [F3].
Thiosulfuric acid
go.drugbank.com/drugs/DB09499ApprovedInvestigational[A252827] Sodium thiosulfate is rapidly degraded in the stomach; therefore, it is normally administered through other routes, such as intravenous or topical. … Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has a variety of industrial uses, including food preservative, water de-chlorinator and paper pulp bleaching
D-glucose
go.drugbank.com/drugs/DB01914ApprovedInvestigationalVet approvedIt circulates in human circulation as blood glucose and acts as an essential energy source for many organisms through aerobic or anaerobic respiration and fermentation. … L-glucose is a synthesized enantiomer that is used as a low-calorie sweetener and laxative.
Mixtures: As 3, Haemonetics Additive Solution Formula 3 (AS-3)Products: AGF Mesenchymal Capillary 5 pcsAstemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnIt was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Mixtures: PAX DIAProducts: HAS TABLETASParaldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties.
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin … [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650]
Tocofersolan
go.drugbank.com/drugs/DB11635ApprovedD-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe as an orally bioavailable source of vitamin E in children suffering from cholestasis [L2371]. … It was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop.
Chlormerodrin
go.drugbank.com/drugs/DB00534ApprovedWithdrawnChlormerodrin is a mercurial compound with toxic side effects that was previously used as a diuretic. The radiolabeled form has been used as a diagnostic and research tool. … It is no longer used and has been replaced with new classes of diuretic drugs.
Rivaroxaban
go.drugbank.com/drugs/DB06228ApprovedInvestigationalRivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg...
Products: PMS-rivaroxabanTralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalTralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the … [A242432] It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis.